Literature DB >> 25643015

ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome.

Jesús Aibar1, Pedro Castro, Gerard Espinosa, Sara Fernández, Cristina Hernández, Mariano Rinaudo, Montserrat Butjosa, Dolors Tàssies, Joan Carles Reverter, Josep Maria Nicolás.   

Abstract

PURPOSE: Decreased ADAMTS-13 (A Disintegrin and Metalloprotease with a ThromboSpondin type 1 motif, member 13) seems to be associated with a poor prognosis in sepsis. However, its role in different septic syndromes and other causes of systemic inflammatory response syndrome (SIRS) remains unclear. The aims of this study were to assess ADAMTS-13 levels in patients with septic syndromes or noninfectious SIRS and to determine their association with morbidity and mortality.
METHODS: The study population consisted of 178 patients admitted to the medical intensive care unit presenting either septic syndromes or noninfectious SIRS. ADAMTS-13 levels were analyzed.
RESULTS: Patients with septic syndromes showed significantly lower levels of ADAMTS-13 compared with those with noninfectious SIRS (P = 0.014). Patients with severe sepsis or septic shock presented lower levels than those of patients with sepsis (P = 0.086). A significant negative correlation was found between ADAMTS-13 levels and delta Sequential Organ Failure Assessment and Acute Physiology and Chronic Health Evaluation II scores at admission in the septic patients. Patients who died had significantly lower levels of ADAMTS-13 compared with survivors, both in the whole population and among the septic patients (P = 0.002 and P = 0.009, respectively). Logistic regression analysis showed that decreased ADAMTS-13 levels were associated with an increased risk of in-intensive care unit mortality (odds ratio, 0.985; 95% confidence interval, 0.973-0.998; P = 0.023).
CONCLUSIONS: Septic patients have lower levels of ADAMTS-13 than do patients with noninfectious SIRS. Levels of ADAMTS-13 are correlated with illness severity in patients with septic syndromes. ADAMTS-13 levels were associated with an increased risk of mortality in critically ill patients with SIRS especially those with septic syndromes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25643015     DOI: 10.1097/SHK.0000000000000341

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  12 in total

1.  Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis.

Authors:  Jainn-Jim Lin; Oi-Wa Chan; Hsiang-Ju Hsiao; Yu Wang; Shao-Hsuan Hsia; Cheng-Hsun Chiu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 2.  The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.

Authors:  Felice Gragnano; Simona Sperlongano; Enrica Golia; Francesco Natale; Renatomaria Bianchi; Mario Crisci; Fabio Fimiani; Ivana Pariggiano; Vincenzo Diana; Andreina Carbone; Arturo Cesaro; Claudia Concilio; Giuseppe Limongelli; Mariagiovanna Russo; Paolo Calabrò
Journal:  Mediators Inflamm       Date:  2017-05-28       Impact factor: 4.711

Review 3.  Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.

Authors:  Seena Tabibi; Tara Tabibi; Rosalynn R Z Conic; Nassim Banisaeed; Michael B Streiff
Journal:  J Intensive Care Med       Date:  2020-07-15       Impact factor: 3.510

4.  Assessment of ADAMTS-13 Level in Hospitalized Children with Serious Bacterial Infections as a Possible Prognostic Marker.

Authors:  Linda Rautiainen; Anna Cirko; Jana Pavare; Reinis Balmaks; Ilze Grope; Irina Katirlo; Gita Gersone; Peteris Tretjakovs; Dace Gardovska
Journal:  Medicina (Kaunas)       Date:  2019-08-20       Impact factor: 2.430

Review 5.  Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.

Authors:  Sahar Balagholi; Rasul Dabbaghi; Peyman Eshghi; Seyed Asadollah Mousavi; Farhad Heshmati; Saeed Mohammadi
Journal:  Transfus Apher Sci       Date:  2020-11-02       Impact factor: 1.764

6.  ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study.

Authors:  Hironori Matsumoto; Jun Takeba; Kensuke Umakoshi; Satoshi Kikuchi; Muneaki Ohshita; Suguru Annen; Naoki Moriyama; Yuki Nakabayashi; Norio Sato; Mayuki Aibiki
Journal:  Thromb J       Date:  2021-03-12

7.  Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes.

Authors:  María P Fernández-Pérez; Sonia Águila; Laura Reguilón-Gallego; Ascensión M de Los Reyes-García; Antonia Miñano; Carlos Bravo-Pérez; María E de la Morena; Javier Corral; Nuria García-Barberá; José M Gómez-Verdú; Enrique Bernal; María T Herranz; Vicente Vicente; Constantino Martínez; Rocío González-Conejero; María L Lozano
Journal:  Clin Transl Med       Date:  2021-01

8.  Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study.

Authors:  Renyu Ding; Zhong Wang; Yuan Lin; Baoyan Liu; Zhidan Zhang; Xiaochun Ma
Journal:  Blood Coagul Fibrinolysis       Date:  2018-09       Impact factor: 1.276

9.  Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series.

Authors:  Abdulrahman Alharthy; Fahad Faqihi; Ziad A Memish; Abdullah Balhamar; Nasir Nasim; Ahmad Shahzad; Hani Tamim; Saleh A Alqahtani; Peter G Brindley; Dimitrios Karakitsos
Journal:  Artif Organs       Date:  2020-12-26       Impact factor: 2.663

10.  Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes.

Authors:  Sara Fernández; Ana B Moreno-Castaño; Marta Palomo; Julia Martinez-Sanchez; Sergi Torramadé-Moix; Adrián Téllez; Helena Ventosa; Ferran Seguí; Ginés Escolar; Enric Carreras; Josep M Nicolás; Edward Richardson; David García-Bernal; Carmelo Carlo-Stella; José M Moraleda; Paul G Richardson; Maribel Díaz-Ricart; Pedro Castro
Journal:  Shock       Date:  2022-01-01       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.